Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer
® biologics and pre|CISION™ tumour targeted chemotherapies. The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal s immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture. Avacta s pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful an
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Triarii service expansion to include Microsoft Azure Sentinel
Falanx Group Limited (FLX.L), the AIM listed provider of cyber security and strategic intelligence services, is pleased to announce a significant expansion of its cyber security service offerings.
In August 2020, Falanx announced the launch of Triarii, its new Managed Detection and Response ( MDR ) service. Triarii uses a combination of both best-of-breed and enterprise-class external components whilst remaining technology-agnostic. This gives the Group the advantage of leveraging the most appropriate technologies to deliver the client solution whilst not being restricted to any one vendor. The initial launch of Triarii has been well received and interest continues to grow at pace. Consequently, our sales pipeline of opportunities continues to strengthen both in quantum and quality.